Novo Nordisk’s stock slumps after failed trial — adding to the company’s woes

Reported by MarketWatch · Published 31 Jul 2026, 9:54 PM MYT (56 min ago)

Summary

The Danish healthcare company’s stock slumped on Friday after it announced the Phase 3 trial failure.

Source & full coverage: this summary is aggregated from MarketWatch, the original publisher. Read the complete report for full context, data and quotes.

Read the original report at MarketWatch →

Most Recent

Novo Nordisk’s stock slumps after failed trial — adding to the company’s woes 56 min ago Apple heads for $460 billion wipeout with its stock seeing worst post-earnings drop in 13 years 59 min ago Is spending thousands of dollars on an AI certification worth it? Here’s how to decide. 1 hr ago US Treasury informed banks that it may intervene in yen, source says 1 hr ago Circle secures New York trust charter as crypto regulatory push accelerates 1 hr ago Coinbase's weak quarter leaves Wall Street split on timing of a recovery 1 hr ago

EconPulse

Markets. Economy. Malaysia & The World.

Independent economic news aggregation for Malaysia, Asia and global markets, updated throughout the day.

Company

About Us Editorial Standards & Corrections Privacy Policy

Work With Us

Submit a Press Release Partnerships & Advertising Contact Us RSS Feed

Contact

editor@econpulse.my

Editorial & newsroom enquiries answered within 1–2 business days.

Novo Nordisk’s stock slumps after failed trial — adding to the company’s woes

Summary

More in Markets

Apple heads for $460 billion wipeout with its stock seeing worst post-earnings drop in 13 years

Is spending thousands of dollars on an AI certification worth it? Here’s how to decide.

ExxonMobil, Chevron’s combined profits quadrupled in three months as the Iran war raged

The Big Mac Index turns 40. Here’s why it’s still relevant.

Fed dissenters speak: Why they backed higher interest rates

New York sues Kalshi, says prediction market is running 'illegal gambling operation'